share_log

Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62

Benzinga ·  Jan 4 04:47

Citigroup analyst David Hoang initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $62.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment